Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Mr. Hiroyuki Minoura, Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Japan

Mr. Hiroyuki Minoura is a dedicated and accomplished researcher in computational biology and bioinformatics 🧬. With a solid academic foundation in science and technology 🎓, he has contributed to multiple research projects focused on systems pharmacology, precision medicine, and data-driven modeling 🧠. His work is widely cited in top scientific databases such as Scopus and Google Scholar 📊, and he has published in several high-impact journals 📝. Mr. Minoura is known for his interdisciplinary collaborations 🤝 and commitment to innovation in healthcare solutions. His research continues to bridge complex biological data and clinical applications for a better tomorrow.

Publication Profile 

Google Scholar

Education

Mr. Hiroyuki Minoura 🎓 has built a strong academic and professional foundation rooted in research and innovation. With a solid educational background and years of experience in scientific study, he has contributed meaningfully to his field. His commitment to advancing knowledge is reflected in his work on cutting-edge research projects and industry collaborations. 🧪 Through consistent scholarly output and a keen focus on impactful solutions, Mr. Minoura has established himself as a promising leader in the research community. 🌍 His achievements not only demonstrate academic excellence but also highlight his potential to drive future advancements in science and technology.

Research and Innovations

Mr. Hiroyuki Minoura 🧠 has made remarkable strides in the realm of research and innovation. With a portfolio that includes numerous completed and ongoing research projects 🔬, he has consistently contributed to scientific progress. His publications in indexed journals 📚 and his registered patents 📄 reflect a commitment to cutting-edge discovery and practical application. Mr. Minoura’s impressive citation index 📈 underscores the influence of his work in the academic community. Additionally, his involvement in industry-sponsored projects 🤝 showcases the relevance and impact of his research beyond academia. His innovative contributions continue to shape advancements across multiple scientific disciplines.

Research Focus

Mr. Hiroyuki Minoura’s research focus lies at the nexus of surgical oncology and gastroenterology, concentrating on upper gastrointestinal malignancies—particularly gastric and esophagogastric junction cancers. 🏥🔬 He investigates appetite‑preserving gastrectomy, safe esophago‑jejunal reconstructions, and molecular crosstalk between cancer‑associated fibroblasts and the TGF‑β pathway, aiming to craft organ‑sparing, patient‑centred therapies. 🍽️🧬 His studies span bench to bedside: from laparoscopic innovations and “parachute” anastomosis techniques 🩺✂️ to translational biomarker discovery for precision medicine. 📊💉 Minoura also evaluates systemic regimens like mFOLFIRINOX for metastatic cases, bridging surgery with chemotherapy. 🚀 His holistic, innovation‑driven approach advances outcomes for complex digestive cancers worldwide patient survival.

Publication Top Notes

Abdellatif Benraiss | Gene Therapy |

Published on by Top Pharmaceutical

Abdellatif Benraiss | Gene Therapy | Best Researcher Award

Dr. Abdellatif Benraiss, Universiy of Rochester, United States

Dr. Abdellatif Benraiss is a distinguished neuroscientist 🧠 specializing in neurobiology, stem cell research 🌱, and gene therapy 🧬. With academic roots in Morocco 🇲🇦 and France 🇫🇷, he earned his Ph.D. in Neurobiology in 1996. His postdoctoral and faculty work in top institutions like Cornell University 🇺🇸 and the University of Rochester has led to pioneering research in Huntington’s disease 🧩, gene transfer therapies 💉, and adult brain regeneration 🧪. He is an esteemed member of several scientific societies 🌍 and a recipient of prestigious awards, including the 2022 Huntington’s Disease Foundation Research Award 🏆.

Publication Profile

Google Scholar

Education

Dr. Abdellatif Benraiss began his academic journey in Morocco 🇲🇦, earning a B.S. in Animal Biology 🐾 from Cadi Ayyad University in 1990. He continued his studies in France 🇫🇷 at Aix-Marseille II University, receiving a second B.S. in Genetics 🧬 in 1991, an M.S. in Neurobiology 🧠 in 1992, and a Ph.D. in Neurobiology in 1996. Pursuing advanced research, he completed a postdoctoral fellowship in Molecular Neurobiology 🔬 at Cornell University Medical College, New York 🇺🇸 (1997–2002), and earned an HDR degree in Gene Therapy 💉 from René Descartes University, Paris, in 2004.

Awards

Dr. Abdellatif Benraiss has been recognized with numerous prestigious honors for his groundbreaking work in neuroscience and gene therapy 🧠💉. In 2022, he received the Huntington’s Disease Foundation Research Award 🧬. He was awarded the NYSTEM Investigator-Initiated Research Project Award in 2011 🧪. His contributions to neurodegenerative disease research earned him the European Leukodystrophy Association (ELA) Award in both 2004 and 2005 🧠🌍. Earlier, in 2003 and 2004, he received fellowships from the French Muscular Dystrophy Association (AFM) 💪🇫🇷. In 2001, he was honored with the Aging Foundation Award from Cornell Medical School 🏛️📜.

Research Focus

Dr. Abdellatif Benraiss’s research focuses on neuroregeneration, gene therapy, and glial cell biology within the context of neurodegenerative diseases 🧠💉. He has pioneered studies on induced neurogenesis in the adult brain, particularly in Huntington’s disease models 🧬, demonstrating how new neurons and glial cells can slow disease progression. His innovative work in gene transfer technologies using viral vectors has contributed to therapies for disorders like metachromatic leukodystrophy and Alzheimer’s disease 🧪. He also explores glial chimerism, aiming to replace diseased brain cells with healthy ones. His multidisciplinary research bridges stem cell therapy, molecular neuroscience, and regenerative medicine 🧫🧍‍♂️.

Publication Top Notes

In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus

Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain

SOX9 is an astrocyte-specific nuclear marker in the adult brain outside the neurogenic regions

Nitric oxide negatively regulates mammalian adult neurogenesis

Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter

Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation

Promoter‐targeted selection and isolation of neural progenitor cells from the adult human ventricular zone

Adenovirally expressed noggin and brain-derived neurotrophic factor cooperate to induce new medium spiny neurons from resident progenitor cells in the adult striatal …

Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s …

High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain

Human glia can both induce and rescue aspects of disease phenotype in Huntington disease

Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain

Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease

Neuronal transgene expression in dominant-negative SNARE mice

PDGF-B is required for development of the glymphatic system

Fluorescent Ca2+ indicators directly inhibit the Na,K-ATPase and disrupt cellular functions

Xandra Breakefield | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Xandra Breakefield | Gene Therapy | Best Researcher Award

Prof. Dr. Xandra Breakefield, Massachusetts General Hospital/Harvard Medical School, United States

Prof. Dr. Xandra Breakefield is a pioneering geneticist and neuroscientist specializing in gene therapy and extracellular vesicle research. She earned her Ph.D. from Georgetown University and trained at NIH under Nobel Laureate Dr. Marshall Nirenberg. A Harvard Medical School professor and Massachusetts General Hospital researcher, she has made groundbreaking contributions to neurogenetics and dystonia. Recognized with numerous prestigious awards 🏆, including the Mika Salpeter Lifetime Achievement Award, she ranks among the world’s top scientists. A leader in gene and cell therapy, she serves on advisory boards worldwide 🌍, shaping the future of biomedical research.

Publication Profile

orcid

Education

Prof. Dr. Xandra Breakefield 🎓 embarked on her academic journey with an A.B. in Biology from Wilson College (1960-1965), graduating cum laude for her outstanding performance. During this period, she also enriched her knowledge at American University (1964-1965), deepening her expertise in biology 🧬. Her passion for microbial genetics led her to pursue a Ph.D. at Georgetown University (1967-1971), where she specialized in microbial genetics 🦠. This strong educational foundation set the stage for her groundbreaking contributions to the field, establishing her as a distinguished researcher in genetics and molecular biology. 🌟

Professional Experience

Prof. Dr. Xandra Breakefield 🧬 has had an illustrious career in genetics and neurology. She has been a Geneticist at Massachusetts General Hospital’s Radiology Service since 2002 and a Professor of Neurology at Harvard Medical School since 1996. Previously, she held key roles in molecular neurogenetics at Massachusetts General Hospital 🏥 and directed the Division of Molecular Neurogenetics at the Eunice Kennedy Shriver Center. Her academic journey includes faculty positions at Yale University and Georgetown University 📚. Early in her career, she trained under Nobel Laureate Dr. Marshall Nirenberg at NIH, shaping her expertise in biochemical genetics. 🌟

Awards

Prof. Dr. Xandra Breakefield 🧬 has received numerous prestigious awards for her groundbreaking contributions to neuroscience and genetics. She earned the McKnight Neuroscience Development Award (1982-1984) and two Javits Neuroscience Investigator Awards (1985-1992, 1995-2002). She was honored with an Honorary Doctorate from Wilson College (1991) and an Honorary Master’s Degree from Harvard Medical School (1996) 🎓. Recognized globally, she received the Mika Salpeter Lifetime Achievement Award (2013) and the NIH Director’s WALS Speaker Award (2017). Ranked among the Top 1000 Female Scientists in the World (2022, 2024), her work continues to shape modern molecular medicine. 🌟

Research Focus

Prof. Dr. Xandra O. Breakefield focuses on neuroscience, gene therapy, and extracellular vesicles 🧠🧬🩸. Her research explores how extracellular vesicles facilitate cell-to-cell communication and their potential for delivering gene therapies to treat neurological disorders and cancers. She also investigates glioblastoma, a highly aggressive brain tumor, using cortical organoids 🧪🔬 to study cell-state heterogeneity and intercellular transfer. Her work has significant implications for precision medicine and targeted therapies 🎯💊. As a leading expert in the field, she collaborates on innovative projects integrating genomics, bioengineering, and molecular biology to advance treatments for brain diseases.

Publication Top Notes

Extracellular vesicles for the delivery of gene therapy

Data from Glioblastoma Cortical Organoids Recapitulate Cell-State Heterogeneity and Intercellular Transfer

RNA delivery by extracellular vesicles in mammalian cells and its applications

Versatile Role of Rab27a in Glioma: Effects on Release of Extracellular Vesicles, Cell Viability, and Tumor Progression

Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function

Exosome/microvesicle content is altered in leucine‐rich repeat kinase 2 mutant induced pluripotent stem cell‐derived neural cells

Glioma-Derived miRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells

SON DINH PHONG | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

SON DINH PHONG | Gene Therapy | Best Researcher Award

Dr SON DINH PHONG, DUYTAN UNIVERSITY, Vietnam

Dr. Dinh Phong Son is a dedicated researcher in molecular medicine at Duy Tan University, Vietnam. With a Ph.D. from Guangxi Medical University, China, and a background in laboratory medicine from Hue University of Medicine and Pharmacy, his research focuses on molecular biomarkers for early disease detection 🧪🔬. He explores the LncRNA/CircRNA/miRNA/gene/protein-drug interaction network and gene-editing techniques like CRISPR/Cas9 for targeted therapy. His work on cardiovascular disease and cancer diagnostics has been published in prestigious journals 📚🧑‍🔬. Passionate about advancing molecular biology, he aspires to contribute to innovative breakthroughs in disease research.

Publication Profile

orcid

Education

Dr. Dinh Phong Son 🎓 holds a degree in Laboratory Medicine Technique from Hue University of Medicine and Pharmacy, Vietnam, and a Ph.D. in Molecular Medicine from Guangxi Medical University, China. 🧬 His expertise lies in molecular biology, with a strong focus on disease biomarkers and gene-targeted therapies. 🏥🔬 With a solid academic foundation, he has contributed significantly to scientific advancements, particularly in precision medicine and diagnostics. His research aims to enhance medical treatments by identifying key genetic markers, paving the way for innovative therapeutic approaches. 🌍✨ Dr. Son’s dedication to science continues to drive breakthroughs in healthcare. 💡👨‍⚕️

Research and Innovations

Dr. Son Dinh Phong 🔬 is deeply engaged in advancing molecular biology through next-generation sequencing and online medical databases. His primary focus is identifying potential biomarkers for early disease detection, including diabetes, cardiovascular diseases, stroke, and cancer. 🧬🩺 His research also explores gene-targeted therapies, utilizing CRISPR/Cas9 for gene editing, overexpression, and silencing. 🏥 His studies on LncRNA/CircRNA/miRNA/gene/protein-drug interaction networks provide a foundation for future medical breakthroughs. 📊✨ Committed to innovation, Dr. Son’s ongoing work (2023-2025) aims to drive scientific progress, hoping for greater support to expand molecular biology research worldwide. 🌍💡

Research Contributions

Dr. Son Dinh Phong 🔬 is highly proficient in advanced molecular biology techniques, including PCR, qPCR, and sequencing analysis 🧪🧬. He specializes in CRISPR/Cas9 genome editing, RNA silencing, and overexpression assays, contributing to groundbreaking gene therapy research. 🏥 His expertise also includes cell culture, western blotting, and fluorescence in situ hybridization, essential for studying gene expression and protein interactions. 🔍🧫 Additionally, he excels in bioinformatics and molecular docking simulations, enabling in-depth analysis of gene interactions and drug responses. 💻💊 With a strong foundation in computational biology, Dr. Son continues to drive innovation in precision medicine and molecular diagnostics. 🚀✨

Editorial Appointments

Dr. Son Dinh Phong 🌍🔬 actively contributes to the global scientific community through his extensive research and publications. While specific editorial roles, consultancy projects, or industry collaborations may not be listed, his scholarly work reflects deep engagement in molecular biology and precision medicine. 🧬📖 His ORCID profile further validates his impactful contributions, showcasing his dedication to advancing medical research. 🏥✨ Through collaborations and scientific discourse, Dr. Son continues to push the boundaries of innovation, striving to enhance disease diagnostics and therapeutic strategies. His commitment to research ensures lasting contributions to the ever-evolving field of molecular medicine. 💡🚀

Research Focus

Dr. Son Dinh Phong’s research primarily focuses on cardiovascular diseases 🫀, non-coding RNAs 🧬, and bioinformatics-driven biomarker discovery 🖥️. His work explores circular RNAs (circRNAs) and microRNAs (miRNAs) in coronary heart disease (CHD) 🏥, revealing their role as competing endogenous RNAs (ceRNAs) in gene regulation. Additionally, he investigates serum miRNAs as potential diagnostic biomarkers for various cancers 🎗️ and employs computational approaches 🔬 to identify key regulatory networks in diseases like latent tuberculosis 🦠. His studies integrate molecular biology, genomics, and systems biology to advance precision medicine 🎯 and therapeutic innovations 💊 for complex diseases.

Publication Top Notes

Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on MicroarrayData analysis, molecular docking, and dynamic simulation

Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression by sponging miRNA-338-3p via regulating the expression of ETS1

Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of bioinformatics data

Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as potential biomarker for coronary heart disease

Construction of miRNAs and gene expression profiles associated with ischemic cardiomyopathy: Bioinformatics analysis

Prof. Stefano Rivella|Hematology and Gene Therapy| Best Researcher Award

Published on by Top Pharmaceutical

Prof. Stefano Rivella, Hematology and Gene Therapy ,Best Researcher Award

Prof. Stefano Rivella at Children’s Hospital of Philadelphia/University of Pennsylvania,United States

PROFILE  

Orcid

🎓 Early Academic Pursuits :

Stefano Rivella’s academic journey began in Italy, where he pursued his Bachelor of Science (BSc) and Doctor of Philosophy (PhD) at the University of Pavia. His dedication to the field of genetics was evident early on, as he received Italy’s Best University Thesis award from the Italian Genetics Institute (AGI) in 1991. Following his doctoral studies, Dr. Rivella remained at the University of Pavia as a Pre and Doctoral Trainee until 1997. His postdoctoral training took him to the prestigious Memorial Sloan Kettering Cancer Center, where he deepened his expertise in gene therapy and hematology.

🧬 Professional Endeavors :

Dr. Rivella’s professional career is marked by significant contributions to genetic medicine and pediatrics. He began his faculty appointments at Weill Cornell Medical College in 2002, where he served as an Assistant Professor of Genetic Medicine in Pediatrics. His innovative work in gene therapy and pediatrics led to his promotion to Associate Professor in both the Pediatrics and Graduate School divisions by 2008.

In 2015, Dr. Rivella transitioned to the Children’s Hospital of Philadelphia (CHOP), where he became a Professor of Pediatrics. His expertise and impact in the field were further recognized when he was appointed the Kwame Ohene-Frempong Endowed Chair in Pediatric Hematology later that year. Currently, he leads the RNA Gene Therapeutics group at The Penn Institute for RNA Innovation, a role he took on in 2023. This position underscores his leadership in pioneering RNA-based therapies for genetic disorders.

🔬 Contributions and Research Focus :

Dr. Rivella’s research has focused on gene therapy, particularly in the treatment of hemoglobinopathies such as thalassemia. His work has been instrumental in the development of innovative therapeutic strategies, including the approval of the clinical trial “ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia,” which is a significant milestone in the field. This trial, sponsored by the Children’s Hospital of Philadelphia, utilizes the ALS20 vector generated in Dr. Rivella’s laboratory, reflecting his deep involvement in cutting-edge therapeutic development.

His expertise extends beyond academia, as he has served as a consultant for several major pharmaceutical companies, including Novartis, Ionis, and Merck. Dr. Rivella has also played a critical role in designing clinical trials and analyzing data for various drugs, contributing to the advancement of gene therapy and hematology on a global scale.

🏆 Accolades and Recognition :

Dr. Rivella’s contributions to the field have been widely recognized through numerous awards and honors. Early in his career, he received multiple Travel Grant Awards from prestigious organizations such as the International Society of Experimental Hematology (ISEH) and the American Society of Gene & Cell Therapy (ASGCT). Notably, in 2015, he was honored with the Sultan bin Khalifa International Thalassemia Federation Award for Innovative Medical Research, highlighting his impact on thalassemia treatment.

In 2019, Dr. Rivella was awarded the Marcel Simon Award by the International BioIron Society (IBIS), further cementing his status as a leader in the field of iron metabolism and hematology. His most recent accolade, the Outstanding Poster Award in 2024 for his work on lentiviral gene therapy, underscores his ongoing contributions to cutting-edge research in gene therapy.

🌍 Impact and Influence :

Dr. Rivella’s influence extends beyond his immediate research contributions. As a member and leader of various scientific societies, including the American Society of Hematology (ASH) and the International BioIron Society (IBIS), he has helped shape the direction of research and clinical practice in hematology and gene therapy. His role on the Scientific Advisory Boards (SAB) of several biopharmaceutical companies allows him to directly impact the development of new therapies, ensuring that innovative treatments reach patients.

🏅 Legacy and Future Contributions :

Dr. Rivella’s legacy in pediatric hematology and gene therapy is profound. Through his work, countless patients with hemoglobinopathies and other genetic disorders have new hope for effective treatments. His pioneering efforts in RNA gene therapeutics promise to revolutionize the field, offering novel approaches to previously intractable conditions.

As he continues his research and leadership at CHOP and The Penn Institute for RNA Innovation, Dr. Rivella’s future contributions are poised to further advance the field of gene therapy. His commitment to education, research, and clinical excellence ensures that his legacy will endure, inspiring future generations of scientists and clinicians dedicated to improving the lives of patients with genetic disorders.

🎓Publication 

Iron restriction in sickle cell disease: When less is more

  • Authors   :Oswaldo L. Castro; Lucia De Franceschi; Tomas Ganz; Julie Kanter; Gregory J. Kato; Sant‐Rayn Pasricha; Stefano Rivella; John C. Wood
  • Journal    :American Journal of Hematology
  • Year         :2024

Optimizing lentiviral genomic integrations to cure beta-thalassemia: The least required for success?

    • Authors :Stefano Rivella
    • Journal   :
      Molecular Therapy – Methods & Clinical Development
    • Year       : 2024

Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis

  • Authors  :Raymond Liang; Miao Lin; Vijay Menon; Jiajing Qiu; Anagha Menon; Laura Breda; Tasleem Arif; Stefano Rivella; Saghi Ghaffari
  • Journal    :Blood Advances
  • Year         :  2023.

DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia

  • Authors  :L. K. Metthew Lam; Sophia Murphy; Dimitra Kokkinaki; Alessandro Venosa; Scott Sherrill-Mix; Carla Casu; Stefano Rivella; Aaron Weiner; Jeongho Park; Sunny Shin et al
  • Journal   :
    Science Translational Medicine
  • Year        :   2021

Red Blood Cells Function as DNA Sensors

  • Authors  :Metthew Lam; Sophia Murphy; Dimitra Kokkinaki; Alessandro Venosa; Scott Sherrill-Mix; Carla Casu; Stefano Rivella; Aaron Weiner; Jeongho Park; Sunny Shin et al.
  • Journal   :Preprint
  • Year        :  2021